S'abonner

Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications - 05/01/22

Doi : 10.1016/j.jaci.2021.06.008 
Miranda L. Abyazi, BS a, Kayla A. Bell, BS a, Gavin Gyimesi, BS b, Turner S. Baker, BS c, Minji Byun, PhD c, Huaibin M. Ko, MD e, Charlotte Cunningham-Rundles, MD, PhD c, Feng Feng, PhD d, Paul J. Maglione, MD, PhD a,
a Pulmonary Center and Section of Pulmonary, Allergy, Sleep & Critical Care, Department of Medicine, Boston University School of Medicine, Boston, Mass 
b Department of Biological Sciences, Fordham University, Bronx, NY 
c Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 
d Department of Microbiology, Boston University School of Medicine, Boston, Mass 
e Department of Pathology & Cell Biology, Columbia University College of Physicians & Surgeons, New York, NY 

Corresponding author: Paul J. Maglione, MD, PhD, Boston University School of Medicine, Pulmonary Center, 72 East Concord St, R304, Boston, MA 02118.Boston University School of MedicinePulmonary Center72 East Concord StR304BostonMA02118

Abstract

Background

Noninfectious complications are the greatest cause of morbidity and mortality in common variable immunodeficiency (CVID), but their pathogenesis remains poorly defined.

Objective

Using high-throughput approaches, we aimed to identify, correlate, and determine the significance of immunologic features of CVID with noninfectious complications (CVIDc).

Methods

We simultaneously applied proteomics, RNA sequencing, and mass cytometry to a large cohort with primary antibody deficiency.

Results

CVIDc is differentiated from uncomplicated CVID, other forms of primary antibody deficiency, and healthy controls by a distinct plasma proteomic profile. In addition to confirming previously reported elevations of 4-1BB, IL-6, IL-18, and IFN-γ, we found elevations of colony-stimulating factor 1, IL-12p40, IL-18R, oncostatin M, TNF, and vascular endothelial growth factor A to differentiate CVIDc. This cytokine dysregulation correlated with deficiency of LPS-specific antibodies and increased soluble CD14, suggesting microbial translocation. Indicating potential significance of reduced LPS-specific antibodies and resultant microbial-induced inflammation, CVIDc had altered LPS-induced gene expression matching plasma proteomics and corresponding with increased CD14+CD16 monocytes, memory T cells, and tissue inflammation ameliorated by T-cell–targeted therapy. Unsupervised machine learning accurately differentiated subjects with CVIDc and supported cytokine dysregulation, antibody deficit, and T-cell activation as defining and convergent features.

Conclusions

Our data expand understanding of CVIDc proteomics, establish its link with deficiency of IgA and LPS-specific antibodies, and implicate altered LPS-induced gene expression and elevated monocytes and T cells in this cytokine dysregulation. This work indicates that CVIDc results when insufficient antibody neutralization of pathogen-associated molecular patterns, like LPS, occurs in those with a heightened response to these inflammatory mediators, suggesting a 2-hit model of pathogenesis requiring further exploration.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Common variable immunodeficiency, CVID, lipopolysaccharide, LPS, noninfectious complications, IL-12, IFN-γ, TNF, monocytes, T cells

Abbreviations used : CVID, CVIDc, HC, MFA, PAD, PAMP, sCD14, TCM


Plan


 This work was funded by the National Institutes of Health (grant nos. AI137183 and AI151486), an AAAAI Foundation Faculty Development Award, investigator-initiated grants from Horizon Pharma and Takeda, and a Career Investment Award from Boston University (all to P.J.M.). The funding sources were not involved in the collection, analysis, interpretation of data, preparation of the manuscript, or the decision to submit this report for publication.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2021  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 149 - N° 1

P. 315 - janvier 2022 Retour au numéro
Article précédent Article précédent
  • Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21
  • SuJin Hwang, Christina Tatsi, Hye Sun Kuehn, Julie E. Niemela, Jennifer Stoddard, Yan Su, Maya Lodish, Gulbu Uzel, Rosanne Spolski, Warren J. Leonard, Steven M. Holland, Thomas A. Fleisher, Constantine A. Stratakis, Sergio D. Rosenzweig
| Article suivant Article suivant
  • Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy, and enteropathy, and implications for clinical management
  • Sarah K. Baxter, Tom Walsh, Silvia Casadei, Mary M. Eckert, Eric J. Allenspach, David Hagin, Gesmar Segundo, Ming K. Lee, Suleyman Gulsuner, Brian H. Shirts, Kathleen E. Sullivan, Michael D. Keller, Troy R. Torgerson, Mary-Claire King

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.